Sisram Medical Ltd. (1696) AI Stock Analysis

• Market Cap: HK$2.04B
• Dividend Yield: 3.62%
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): 10.4
• Beta (1Y): 1.25
• Revenue Growth: -3.16%
• EPS Growth: -20.69%
• Country: HK
• Employees: 1,000
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Devices
• EPS (TTM): 0.24
• Shares Outstanding: 468,343,080
• 10 Day Avg. Volume: 1,006,460
• 30 Day Avg. Volume: 1,081,416
• PEG Ratio: 0.53
• Price to Book (P/B): 1.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.59
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 0.35
• Enterprise Value/Gross Profit: 2.27
• Enterprise Value/Ebitda: 2.94
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 71 Outperform
• Price Target: HK$5.00 ▲(14.68%Upside)

Sisram Medical Ltd.'s overall stock score reflects its strong financial foundation and attractive valuation. However, the lack of strong technical momentum and challenges in cash flow growth weigh down the score. Investors may find value in the stock due to its low P/E ratio and stable financial metrics but should be cautious of the slight bearish technical indicators.

Sisram Medical Ltd. Business Overview & Revenue Model

Company Description

Sisram Medical Ltd. (1696) is a leading global provider of medical aesthetic devices headquartered in Hong Kong. The company operates within the medical aesthetics industry, offering a comprehensive range of products and services designed to enhance the well-being and appearance of individuals. Its core products include energy-based devices for skin rejuvenation, hair removal, and body contouring, catering to both professional and consumer markets worldwide.

How the Company Makes Money

Sisram Medical Ltd. generates revenue primarily through the sale of its medical aesthetic devices to healthcare professionals, clinics, and distributors around the globe. The company leverages a robust distribution network and strategic partnerships to expand its market reach and drive sales. Revenue streams include direct sales of cutting-edge equipment, after-sales services, and consumables required for device operation. Additionally, Sisram Medical may engage in collaborative agreements with clinics and hospitals to promote its products, thereby increasing adoption and generating consistent income. By maintaining innovation in product development and expanding its service offerings, the company sustains a competitive edge in the medical aesthetics sector.

Sisram Medical Ltd. Financial Statement Overview

Summary

Sisram Medical Ltd. is financially sound with strong revenue growth and stable balance sheet metrics. However, the company faces challenges in maintaining consistent profitability and cash flow growth. Continued focus on managing costs and improving cash flow stability will be crucial for future success.

Income Statement

Sisram Medical Ltd. has demonstrated a steady revenue growth over the years, although 2024 saw a slight decline. Gross profit margins have remained strong, reflecting efficient cost management. However, the net profit margin has shown some fluctuation, indicating potential volatility in profitability.

Balance Sheet

The balance sheet of Sisram Medical Ltd. is robust, with a healthy equity ratio and low debt-to-equity ratio, indicating financial stability. The company has maintained a strong stockholders' equity position over the years, suggesting a solid foundation for future growth.

Cash Flow

While Sisram Medical Ltd. has maintained positive operating cash flow, free cash flow growth has been inconsistent, with some periods of decline. The free cash flow to net income ratio suggests a reasonable conversion of profits into cash, but improvements are needed to ensure consistent liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	349.11M	359.29M	354.48M	294.29M	162.09M
Gross Profit	216.68M	219.53M	202.23M	166.86M	90.30M
EBITDA	38.91M	53.43M	58.38M	55.96M	28.19M
Net Income	25.13M	31.50M	40.17M	31.25M	13.34M
Balance Sheet
Total Assets	627.26M	613.50M	555.60M	530.13M	431.81M
Cash, Cash Equivalents and Short-Term Investments	71.98M	70.60M	81.41M	152.92M	116.37M
Total Debt	43.20M	44.68M	41.34M	41.62M	37.06M
Total Liabilities	142.47M	143.98M	123.38M	126.51M	99.92M
Stockholders Equity	464.03M	452.31M	430.87M	402.18M	331.89M
Cash Flow
Free Cash Flow	30.38M	35.37M	-42.28M	29.41M	16.46M
Operating Cash Flow	33.08M	43.94M	22.04M	32.38M	25.74M
Investing Cash Flow	-6.59M	-32.99M	-52.11M	-46.77M	-33.51M
Financing Cash Flow	-16.11M	-20.97M	-17.85M	55.78M	-12.21M

Sisram Medical Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.36
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Negative. The current price of 4.36 is below the 20-day moving average (MA) of 4.64, below the 50-day MA of 4.39, and above the 200-day MA of 3.92, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.17 is Neutral, neither overbought nor oversold. The STOCH value of 44.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1696.

Sisram Medical Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1789	75 Outperform	HK$6.72B	22.54	10.92%	1.20%	20.19%	45.54%
1302	72 Outperform	HK$8.59B	36.51	6.49%	―	0.87%	-18.05%
1696	71 Outperform	HK$2.04B	10.42	5.49%	3.62%	-3.16%	-20.69%
6669	71 Outperform	€2.70B	45.70	3.90%	―	10.44%	238.85%
Sector *	60 Neutral	HK$15.14B	5.56	-7.43%	4.30%	11.60%	-21.06%
9996	51 Neutral	€4.27B	―	-10.43%	―	36.76%	42.89%

Sisram Medical Ltd. Corporate Events

Sisram Medical Ltd Announces Board Committee Restructuring

Sisram Medical Ltd has announced changes in the composition of its board committees, effective June 24, 2025. These changes involve the appointment of new members and chairpersons for the audit, remuneration, and nomination committees, potentially impacting the company’s governance and strategic direction.

Sisram Medical Ltd Updates Board of Directors

Sisram Medical Ltd has announced the updated list of its board of directors and their roles, effective June 24, 2025. This update in leadership structure, including executive, non-executive, and independent non-executive directors, may influence the company’s strategic direction and governance, potentially impacting its stakeholders and market positioning.

Sisram Medical Ltd Updates Nomination Committee Terms

Sisram Medical Ltd has updated the terms of reference for its Nomination Committee, which was originally established in 2017. The committee will consist of at least three members, primarily independent non-executive directors, and will ensure diversity with at least one director of a different gender. This move is likely to strengthen the company’s governance structure, potentially enhancing its industry positioning and stakeholder confidence.

Sisram Medical Ltd Successfully Concludes Annual General Meeting

Sisram Medical Ltd held its Annual General Meeting on June 24, 2025, where all proposed resolutions were passed. Key resolutions included the re-election of directors and the reappointment of auditors, as well as mandates for share buybacks and issuance. This demonstrates strong shareholder support and positions the company for strategic flexibility in its operations.

Sisram Medical Enters Strategic Supply Agreement with Fosun Wanbang

Sisram Medical Ltd has entered into a Supply Framework Agreement with Fosun Wanbang (Jiangsu) to supply botulinum toxin type A for injection, known as DAXXIFY®, in Mainland China. This agreement aligns with Sisram’s business model and is expected to generate additional revenue, enhancing its market position. The collaboration with Fosun Wanbang, a qualified institution for distributing medical toxins in China, is strategically beneficial due to its independence from competitors and nationwide distribution capabilities. This partnership supports Sisram’s long-term commercial planning and operational efficiency.

Sisram Medical Ltd Announces 2025 Annual General Meeting Agenda

Sisram Medical Ltd has announced its upcoming annual general meeting scheduled for June 24, 2025, in Hong Kong. Key agenda items include the re-election of several directors and the re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for mandates to buy back shares and issue additional shares, which could impact its market operations and shareholder value.